A Phase I Study of LY3537982 in People with Solid Tumors with a G12C Mutation in the KRAS Gene

Share

Full Title

A Phase 1a/1b Study of LY3537982 in Patients with KRAS G12C-Mutant Advanced Solid Tumors

Purpose

A mutation called G12C in a gene called KRAS may promote cancer growth. LY3537982 is an investigational drug that targets the mutated KRAS G12C protein. This targeting action may stop cancer cells from growing and dividing.

In this study, researchers are seeking to find the highest dose of LY3537982 that can be given safely in people with advanced solid tumor cancers containing a KRAS G12C mutation. LY3537982 is a capsule that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have an advanced, inoperable, or metastatic solid tumor containing a KRAS G12C mutation.
  • Patients should recover from the serious side effects of prior therapies before receiving LY3537982.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

For more information about this study and to ask about eligibility, please contact the office of Dr. Yonina Murciano-Goroff at 646-888-4226.

Protocol

21-389

Phase

I

Disease Status

Newly Diagnosed & Relapsed/Refractory

Co-Investigators

Diseases